Saturday 17 October 2026 Export IFRX’s income statement to Excel — free account

InflaRx N.V.

In the quarter to June 2026, revenue fell 128.9%, EPS grew 54.2% and free cash flow grew 69.3%, each against the same quarter a year earlier.

1.32 0.12 −8.33%

Follow IFRX

Alert me

Market cap: $212.2M
P/E: 0.0×
Fwd P/E: −5.0×
Dividend yield: —
F-score: 2/9
Altman Z: −9.10
Beneish M: n/a
Dividend safety: n/a

Overview Business Profile Financial Analysis Income Statement Balance Sheet Cash Flow Metrics & Ratios 10-Q 10-K

Insider Decisions trades per month

	Dec 25			Mar 26			Jun 26			Sep 26
Buy	—	—	—	—	—	—	—	—	—	—	—	—
Sell	—	—	—	—	—	—	—	—	—	—	—	—

Insider Ownership 0.00%

Capital & Financial Ratios $m

Market Cap 212.21

Revenue 0.03

Net Income (44.71)

Free Cash Flow (27.23)

Net Debt (187.79)

Current Ratio 8.22

Debt/Equity 0.00

P/E ratio 0.00

Fwd P/E (5.01)

P/S ratio 5,075.70

P/B ratio 0.91

Past 5Y EPS Growth —

This Y EPS Growth 58.12%

Next Y EPS Growth (26.82%)

Next Y revenue growth (57.07%)

Next 5Y EPS Growth 14.93%

Green and red mark values outside typical ranges. How we judge →

Valuation vs history

EV/Sales, ten years

P/B against its own 10 years 32.01%

10-year low 10-year high

Dividends

Payout Ratio —

Annual Dividend Rate —

Annual Dividend Yield —

	total	individual payouts
2025	Powerpack
2024	Powerpack
2023	Powerpack
2022	Powerpack
2021	Powerpack
2020	Powerpack
2019	Powerpack
2017	Powerpack

predictions special payouts not included in total or ratios

Assets vs Liabilities $m

	2023	2024	2025	Q'26
Cash	98	63	55	188
Receivables	4	2	2	2
Inventory	12	7	—	—
Other	4	6	4	3
	118	78	61	192

	2023	2024	2025	Q'26
Payables	13	12	6	6
ST’ Debt	—	—	—	—
Other	5	3	8	17
	18	15	15	23

Compound Annual Growth %

	10y	5y	3y
Sales	—	—	—
Cash Flow	—	0.00%	0.00%
Earnings	—	0.00%	0.00%
Book Value	—	(11.97%)	(20.36%)

Revenue $m

	Mar	Jun	Sep	Dec	Year
’26	—	—	—	—	—
’25	—	0	0	—	0
’24	0	0	0	—	0

Fiscal quarters ending in the months shown.

value withheld pending a data check

Operating Cash Flow $m

	Mar	Jun	Sep	Dec	Year
’26	(9)	(3)	—	—	—
’25	(15)	(10)	(11)	(4)	(40)
’24	(16)	(13)	(11)	(12)	(53)
’23	(11)	(12)	(6)	(12)	(41)
’22	(14)	(13)	(2)	(7)	(36)
’21	(13)	(9)	(11)	(14)	(47)
’20	(12)	(8)	(11)	(10)	(42)

Fiscal quarters ending in the months shown.

Free Cash Flow $m

	Mar	Jun	Sep	Dec	Year
’26	(9)	(3)	—	—	—
’25	(15)	(10)	(11)	(4)	(40)
’24	(16)	(13)	(11)	(12)	(53)
’23	(11)	(12)	(6)	(12)	(41)
’22	(14)	(13)	(2)	(7)	(36)
’21	(13)	(9)	(11)	(14)	(47)
’20	(12)	(8)	(11)	(10)	(42)

Fiscal quarters ending in the months shown.

EPS $

	Mar	Jun	Sep	Dec	Year
’26	(0.09)	(0.11)	—	—	—
’25	(0.14)	(0.24)	(0.21)	(0.17)	(0.77)
’24	(0.19)	(0.26)	(0.33)	(0.09)	(0.85)
’23	(0.27)	(0.15)	(0.14)	(0.30)	(0.84)
’22	(0.36)	0.01	(0.18)	(0.18)	(0.71)
’21	(0.22)	(0.40)	(0.32)	(0.33)	(1.30)
’20	(0.35)	(0.42)	(0.29)	(0.38)	(1.44)

Fiscal quarters ending in the months shown.

Group	Line	2016	2017	2018	2019	2020	2021	2022	2023	2024	2025	2026e
Price, $
Price, $	Low	—	14.47	19.00	2.17	2.52	2.23	0.78	1.14	1.17	0.71	Analyst estimates 2026–2028 Powerpack
	High	—	26.92	42.83	53.10	9.70	6.88	4.99	7.25	2.82	2.77
People
People	Employees	17	21	38	45	49	59	48	66	74	65
	Revenue/emp, $m	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Income, $m
Income, $m	Revenue	—	—	—	—	—	—	—	0	0	0
	Gross margin, %	0.00	0.00	0.00	0.00	0.00	0.00	0.00	(743.48)	(1,900.78)	(24,666.87)
	EBT	(10)	(27)	(35)	(60)	(39)	(54)	(31)	(46)	(50)	(52)
	EBT margin, %	0.00	0.00	0.00	0.00	0.00	0.00	0.00	(67,612.15)	(27,781.83)	(155,470.48)
	Net income	(10)	(27)	(35)	(60)	(39)	(54)	(31)	(46)	(50)	(52)
	Depreciation	0	0	0	1	1	1	1	1	1	0
Per share, $
Per share, $	Revenue	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
	Earnings	(351.65)	(2.94)	(1.40)	(2.29)	(1.44)	(1.30)	(0.71)	(0.84)	(0.85)	(0.77)
	Cash flow	(196.63)	(1.46)	(1.12)	(1.86)	(1.54)	(1.13)	(0.80)	(0.74)	(0.89)	(0.59)
	Capex	(2.09)	(0.02)	(0.04)	(0.03)	0.00	0.00	0.00	0.00	0.00	0.00
	Free cash flow	(198.72)	(1.48)	(1.15)	(1.89)	(1.55)	(1.14)	(0.81)	(0.75)	(0.89)	(0.60)
	Book value	(1,011.65)	14.34	7.12	4.61	3.29	2.99	2.11	2.02	1.13	0.70
	Shares, m	0	9	25	26	27	42	44	55	59	67
Valuation, ×
Valuation, ×	P/E	—	—	—	—	—	—	—	0.00	0.00	0.00
	P/S	—	—	—	—	—	—	—	0.00	811.22	2,220.94
	P/B	—	—	—	—	—	—	—	0.81	2.19	1.45
	EV/Sales	—	—	—	—	—	—	—	0.00	461.86	411.26
	EV/FCF	—	—	—	—	—	—	—	0.18	(1.57)	(0.31)
Cash, $m
Cash, $m	Operating cash flow	(6)	(14)	(28)	(48)	(42)	(47)	(36)	(41)	(53)	(40)
	Capex	0	0	(1)	(1)	0	0	0	0	0	0
	Free cash flow	(6)	(14)	(29)	(49)	(42)	(47)	(36)	(41)	(53)	(40)
Balance, $m
Balance, $m	Working capital	31	135	178	118	87	91	89	100	62	46
	Total debt	56	—	—	1	1	2	1	—	—	—
	Net debt	(32)	(139)	(185)	(129)	(93)	(99)	(86)	(98)	(63)	(55)
	Shareholders’ equity	(28)	135	179	120	89	125	93	111	66	47
Returns, %
Returns, %	ROA	(10.88)	(31.66)	(21.44)	(36.80)	(32.77)	(43.39)	(24.28)	(38.81)	(46.94)	(71.35)
	ROIC	0.00	0.00	0.00	0.00	0.00	(136.29)	(500.66)	(295.14)	(1,042.21)	0.00
	ROE	(17.21)	(51.42)	(22.44)	(39.92)	(37.16)	(50.57)	(28.55)	(45.25)	(56.17)	(91.00)

Negative figures in brackets.

All 10 years →

Fiscal years to Dec 2025 · latest quarter Dec 2025

Charts ten years each

Company	Market cap	P/E	Fwd P/E	Revenue growth (Q)	EPS growth (Q)	FCF growth (Q)	Gross margin (Q)	EBIT margin (Q)	Compare
PLX Protalix BioTherapeutics, Inc.	$217.5M	10.9×	10.2×	+27.07% (above 0%: growing)	+2,280.95% (above 0%: growing)	−94.09% (below 0%: shrinking)	60.99%	23.48%	Compare
CAMP CAMP4 Therapeutics Corporation	$216.5M	— (loss-making)	— (loss-making)	+18.84% (above 0%: growing)	n/m	−23.90% (below 0%: shrinking)	100.00%	(752.11%)	Compare
PYXS Pyxis Oncology, Inc.	$215.3M	— (loss-making)	— (loss-making)	—	n/m	−5.46% (below 0%: shrinking)	100.00%	0.00%	Compare
EVMN Evommune Inc.	$215.2M	— (loss-making)	— (loss-making)	—	n/m	+21.78% (above 0%: growing)	100.00%	0.00%	Compare
MGNX MacroGenics, Inc.	$214.7M	— (loss-making)	— (loss-making)	+377.97% (above 0%: growing)	n/m	+12.88% (above 0%: growing)	100.00%	(42.19%)	Compare
ALEC Alector, Inc.	$213.3M	— (loss-making)	— (loss-making)	−57.84% (below 0%: shrinking)	n/m	+30.19% (above 0%: growing)	100.00%	(734.73%)	Compare
IFRX InflaRx N.V.	$212.2M	— (loss-making)	— (loss-making)	−128.93% (below 0%: shrinking)	n/m	+69.33% (above 0%: growing)	14,029.95%	0.00%
ZNTL Zentalis Pharmaceuticals, Inc.	$212.1M	— (loss-making)	— (loss-making)	—	n/m	−9.06% (below 0%: shrinking)	100.00%	0.00%	Compare
LRMR Larimar Therapeutics, Inc.	$206.7M	— (loss-making)	—	—	n/m	−127.63% (below 0%: shrinking)	0.00%	0.00%	Compare
Median of peers	$214.9M	—	—	+22.96%	—	−7.26%	100.00%	0.00%

All 614 Biotechnology stocks →

InflaRx N.V. (IFRX) key facts

Concern: InflaRx N.V. reported a net loss of $51.6 million, or a loss of $0.77 per share, for fiscal 2025.
InflaRx N.V. (IFRX) is a Biotechnology company in the Healthcare sector, listed on Nasdaq.
As of October 16, 2026, IFRX traded at $1.32, a market capitalization of $212.2 million.
Trailing earnings are negative, so a P/E ratio is not meaningful; the stock trades at 5,076× sales.
Return on equity was −91.0% and debt-to-equity 0.00.
Its Piotroski F-score is 2 out of 9 and its Altman Z-score is −9.10 (distress zone) for fiscal 2025.